The purpose of this article is to report the prognostic associations of acute retinal necrosis (ARN), determine the diagnostic utility of aqueous vs vitreous polymerase chain reaction (PCR), and describe outcomes of antiviral, corticosteroid, antithrombotic, and laser retinopexy treatment.
Methods:
A retrospective, nonrandomized case series was conducted. Primary outcomes included final visual acuity (VA), severe VA loss (≥1.00 log of the minimum angle of resolution [logMAR] [Snellen equivalent, <20/200]), and retinal detachment (RD).
Results:
Fifty eyes of 46 patients were diagnosed with ARN. Varicella-zoster and herpes simplex viruses were the viral etiology in 29 and 16 eyes, respectively. Five were diagnosed on clinical criteria. Intravenous acyclovir was administered in 90% of eyes. Neither induction therapy for ≥13 days (P = .692) nor intravitreal medication (P = .203) decreased the incidence of severe vision loss. Maintenance antiviral medication was administered in 96% of eyes (50% received >13 weeks). At final follow-up, 40% of eyes had severe vision loss (range, –0.08 to +3.0 logMAR [Snellen, 20/17-no perception of light]). Forty-six percent developed RD. Relative afferent pupillary defect (RAPD), zone and extent of retinitis, and RD were prognostic of final VA. Antithrombotic therapy was administered in 25/50 eyes and was associated with lower incidence of severe VA loss (P = .027) and better final VA (P = .040). Laser retinopexy was performed in 40% of eyes with no significant effect on RD incidence (P = .901) or severe VA loss (P = .451).
Conclusions:
ARN has a high incidence of RD and poor visual outcomes. Aqueous humor PCR is the first-line diagnostic investigation. Prognostic indicators include RD, RAPD, zone, and extent of retinitis. Induction antiviral medication is appropriate for at least 12 days. Antithrombotic medication is associated with improved outcomes. Laser retinopexy does not reduce the incidence of RD.
UrayamaAYamadaNSasakiT. Unilateral acute uveitis with retinal periarteritis and detachment. Jpn J Clin Ophthalmol. 1971;25:607–619.
2.
HollandGN.Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive Committee of the American Uveitis Society. Am J Ophthalmol. 1994;117(5):663–667. doi:10.1016/S0002-9394(14)70075-3
3.
CochraneTFSilvestriGMcDowellCFootBMcAvoyCE. Acute retinal necrosis in the United Kingdom: results of a prospective surveillance study. Eye (Lond). 2012;26(3):370–377. doi:10.1038/eye.2011.338
4.
HillenkampJNölleBBrunsCRautenbergPFickenscherHRoiderJ. Acute retinal necrosis: clinical features, early vitrectomy, and outcomes. Ophthalmology. 2009;116(10):1971–1975.e2. doi:10.1016/j.ophtha.2009.03.029
5.
Iwahashi-ShimaCAzumiAOhguroN. Acute retinal necrosis: factors associated with anatomic and visual outcomes. Jpn J Ophthalmol. 2013;57(1):98–103. doi:10.1007/s10384-012-0211-y
RoyRPalBPMathurGRaoCDasDBiswasJ. Acute retinal necrosis: clinical features, management and outcomes—a 10 year consecutive case series. Ocul Immunol Inflamm. 2014;22(3):170–174. doi:10.3109/09273948.2013.819928
8.
SimsJLYeohJStawellRJ. Acute retinal necrosis: a case series with clinical features and treatment outcomes. Clin Exp Ophthalmol. 2009;37(5):473–477. doi:10.1111/j.1442-9071.2009.02083.x
9.
HamamRNMansourAEl MollayessG. Positive Epstein-Barr virus polymerase chain reaction in a case of acute retinal necrosis. Can J Ophthalmol. 2012;47(6):e61–e62. doi:10.1016/j.jcjo.2012.07.011
ButlerNJMoradiASalekSS. Acute retinal necrosis: presenting characteristics and clinical outcomes in a cohort of polymerase chain reaction-positive patients. Am J Ophthalmol. 2017;179:179–189. doi:10.1016/j.ajo.2017.05.006
12.
MuthiahMNMichaelidesMChildCSMitchellSM. Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK. Br J Ophthalmol. 2007;91(11):1452–1455. doi:10.1136/bjo.2007.114884
13.
FisherJPLewisMLBlumenkranzM. The acute retinal necrosis syndrome. Part 1: Clinical manifestations. Ophthalmology. 1982;89(12):1309–1316. doi:10.1016/S0161-6420(82)34628-X
14.
KhochtaliSAbrougNKahlounR. Pattern of acute retinal necrosis in a referral center in Tunisia, North Africa. Ocul Immunol Inflamm. 2015;23(5):371–377. doi:10.3109/09273948.2014.925125
15.
MeghparaBSulkowskiGKesenMRTesslerHHGoldsteinDA. Long-term follow-up of acute retinal necrosis. Retina. 2010;30(5):795–800. doi:10.1097/IAE.0b013e3181c7013c
MatsuoTMorimotoKMatsuoN. Factors associated with poor visual outcome in acute retinal necrosis. Br J Ophthalmol. 1991;75(8):450–454. doi:10.1136/bjo.75.8.450
18.
WongRPavesioCELaidlawDAWilliamsonTHGrahamEMStanfordMR. Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome. Ophthalmology. 2010;117(3):556–560. doi:10.1016/j.ophtha.2009.08.003
19.
UsuiYTakeuchiMGotoH. Acute retinal necrosis in Japan. Ophthalmology. 2008;115(9):1632–1633. doi:10.1016/j.ophtha.2008.03.005
20.
KopplinLJThomasASCramerS. Long-term surgical outcomes of retinal detachment associated with acute retinal necrosis. Ophthalmic Surg Lasers Imaging Retina. 2016;47(7):660–664. doi:10.3928/23258160-20160707-08
21.
TibbettsMDShahCPYoungLHDukerJSMaguireJIMorleyMG. Treatment of acute retinal necrosis. Ophthalmology. 2010;117(4):818–824. doi:10.1016/j.ophtha.2009.09.001
22.
TranTHStanescuDCaspers-VeluL. Clinical characteristics of acute HSV-2 retinal necrosis. Am J Ophthalmol. 2004;137(5):872–879. doi:10.1016/j.ajo.2003.12.036
23.
SchoenbergerSDKimSJThorneJE. Diagnosis and treatment of acute retinal necrosis: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124(3):382–392. doi:10.1016/j.ophtha.2016.11.007
24.
CrapottaJAFreemanWRFeldmanRM. Visual outcome in acute retinal necrosis. Retina. 1993;13(3):208–213.
25.
KawaguchiTSpencerDBMochizukiM. Therapy for acute retinal necrosis. Semin Ophthalmol. 2008;23(4):285–290. doi:1080/08820530802111192
26.
MatsuoT. Visual outcome in acute retinal necrosis [correspondence]. Retina. 1994;14(2):192.
27.
MorseLSMizoguchiM. Diagnosis and management of viral retinitis in the acute retinal necrosis syndrome. Semin Ophthalmol. 1995;10(1):28–41. doi:10.3109/08820539509059977
28.
FlaxelCJYehSLauerAK. Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2013;111:133–144.
29.
JeonSKakizakiHLeeWKJeeD. Effect of prolonged oral acyclovir treatment in acute retinal necrosis. Ocul Immunol Inflamm. 2012;20(4):288–292. doi:10.3109/09273948.2012.689073
30.
YehSSuhlerEBSmithJR. Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome. Ophthalmic Surg Lasers Imaging Retina. 2014;45(5):399–407. doi:10.3928/23258160-20140908-02
31.
JabsDANussenblattRBRosenbaumJT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:10.1016/j.ajo.2005.03.057
32.
HollandGNBuhlesWCJrMastreBKaplanHJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy Study Group. Arch Ophthalmol. 1989;107(12):1759–1766. doi:10.1001/archopht.1989.01070020841024
33.
BronAJTripathiRCTripathiBJ. Wolff’s Anatomy of the Eye and Orbit. 8th ed. London, UK: Chapman & Hall Medical; 1997.
34.
SimsJLZamirE. Acute retinal necrosis following steroid treatment for unrecognized Ramsay-Hunt syndrome. Clin Exp Ophthalmol. 2008;36(9):894–895. doi:10.1111/j.1442-9071.2009.01923.x
35.
DukerJSBlumenkranzMS. Diagnosis and management of the acute retinal necrosis (ARN) syndrome. Surv Ophthalmol. 1991;35(5):327–343. doi:10.1016/0039-6257(91)90183-G
36.
CulbertsonWWBlumenkranzMSHainesHGassDMMitchellKBNortonEW. The acute retinal necrosis syndrome. Part 2: Histopathology and etiology. Ophthalmology. 1982;89(12):1317–1325. doi:10.1016/S0161-6420(82)34638-2
37.
TamPMHooperCYLightmanS. Antiviral selection in the management of acute retinal necrosis. Clin Ophthalmol. 2010;4:11–20. doi:10.2147/OPTH.S6390
38.
HuynhTHJohnsonMWComerGMFishDN. Vitreous penetration of orally administered valacyclovir. Am J Ophthalmol. 2008;145(4):682–686. doi:10.1016/j.ajo.2007.11.016
39.
SchulmanJAPeymanGAFiscellaRGPulidoJSugarJ. Parenterally administered acyclovir for viral retinitis associated with AIDS. Arch Ophthalmol. 1984;102(12):1750. doi:10.1001/archopht.1984.01040031416011
BlumenkranzMSCulbertsonWWClarksonJGDixR. Treatment of the acute retinal necrosis syndrome with intravenous acyclovir. Ophthalmology. 1986;93(3):296–300. doi:10.1016/S0161-6420(86)33740-0
42.
PalayDASternbergPJrDavisJ. Decrease in the risk of bilateral acute retinal necrosis by acyclovir therapy. Am J Ophthalmol. 1991;112(3):250–255. doi:10.1016/S0002-9394(14)76725-X
43.
AndoFKatoMGotoSKobayashiKIchikawaHKamiyaT. Platelet function in bilateral acute retinal necrosis. Am J Ophthalmol. 1983;96(1):27–32. doi:10.1016/0002-9394(83)90451-8
44.
LuoYHDuanXCChenBHTangLSGuoXJ. Efficacy and necessity of prophylactic vitrectomy for acute retinal necrosis syndrome. Int J Ophthalmol. 2012;5(4):482–487. doi:10.3980/j.issn.2222-3959.2012.04.15
45.
HanDPLewisHWilliamsGAMielerWFAbramsGWAabergTM. Laser photocoagulation in the acute retinal necrosis syndrome. Arch Ophthalmol. 1987;105(8):1051–1054. doi:10.1001/archopht.1987.01060080053027
46.
ParkJJPavesioC. Prophylactic laser photocoagulation for acute retinal necrosis. Does it raise more questions than answers?Br J Ophthalmol. 2008;92(9):1161–1162. doi:10.1136/bjo.2008.147181
